Drug intelligence / Profile preview

CRMD004

Development stage: Discontinued
Lead developer: CorMedix
Modality: Hydrogel Systems → Drug Delivery Systems
Administration: Parenteral

Overview

**CRMD004** was a preclinical CorMedix catheter-lock product candidate based on licensed Polaschegg technology for a thixotropic antimicrobial gel formulation. It was intended to prevent catheter-related bloodstream infections by serving as a gel lock within an indwelling catheter. CorMedix terminated its license to the underlying technology in November 2015, effective January 2016, citing the narrow patent scope, limited market potential, and the substantial investment required to reinforce the patent estate. The candidate was therefore not advanced to clinical development or commercialization.

Targets

F10 (Factor Xa)F2 (Thrombin)

Beyond the preview

Go deeper on CRMD004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CRMD004.

Explore the full profile